Iovance Biotherapeutics, Inc. Common Stock (IOVA) Stock Price
IOVAStock
$13.62+508.04%52W
Market Cap$6.17B
P/E—
PEG Ratio—
Div yield—
Beta0.77
IOVA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)264.27%
Price vs S&P 500 (4W)34.99%
VGM Score64.64
IOVA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.13 | -$0.11 | +18.43%(+$0.02) | |
| Q1 2026 | -$0.15 | -$0.19 | -23.78%(-$0.04) | |
| Q4 2025 | -$0.18 | -$0.18 | -2.05%(-$0.00) | |
| Q3 2025 | -$0.26 | -$0.25 | +2.85%(+$0.01) | |
| Q2 2025 | -$0.28 | -$0.33 | -19.37%(-$0.05) |
IOVA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
IOVAIovance Biotherapeutics, Inc. Common Stock | D | B | A | 19.0x | 34.5% | 48.4% | — | $13.62 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Iovance Biotherapeutics, Inc. Common Stock
Iovance Biotherapeutics is a biopharmaceutical company developing autologous TIL (tumor-infiltrating lymphocyte) cell therapies for solid tumors. The company's personalized approach harnesses patients' own immune cells to target and destroy cancer cells. Iovance is advancing toward U.S. regulatory approval and commercialization of what could be the first autologous T-cell therapy for solid tumor cancers.